A Randomized Controlled Prophylactic Study of Clofazimine To Prevent Mycobacterium Avium Complex Infection in HIV Disease
Mycobacterium Avium-intracellulare Infection, HIV Infections
About this trial
This is an interventional treatment trial for Mycobacterium Avium-intracellulare Infection focused on measuring AIDS-Related Opportunistic Infections, Mycobacterium avium-intracellulare Infection, Clofazimine, Acquired Immunodeficiency Syndrome
Eligibility Criteria
Inclusion Criteria Concurrent Medication: Allowed: Pneumocystis prophylaxis. Antiretroviral therapy, or other experimental protocols. Antipyretics and analgesics as per the treating physician. Exclusion Criteria Co-existing Condition: Patients with the following are excluded: Unexplained fever. Night sweats. Unexplained anemia with hemoglobin < 10 g percent or hematocrit less than 30 percent. Hepatic transaminase elevations or total bilirubin values of > 3 times normal. Long-term (over 2 weeks) treatment with any drug with known significant anti-Mycobacterium avium complex (MAC) activity including isoniazid, ethambutol, rifampin, raffia, PAS, PZA, amikacin, streptomycin, ethionamide, viomycin, cycloserine, capreomycin, ciprofloxacin, imipenem, rifapentine, gentamicin, or penicillin. Patients with the following are excluded: Known hypersensitivity to clofazimine. Mycobacterium avium complex (MAC) infection diagnosis at any site (except isolation from stool in asymptomatic patient). Any of the following symptoms at the time of study entry: Unexplained fever. Night sweats. Unexplained anemia with hemoglobin < 10 percent or hematocrit less than 30 percent. Hepatic transaminase elevations or total bilirubin values of > 3 times normal. Long-term (over 2 weeks) treatment with any drug with known significant anti-MAC activity. Prior Medication: Excluded: Long-term (over 2 weeks) treatment with any drug with known significant anti-Mycobacterium avium complex (MAC) activity including isoniazid, ethambutol, rifampin, raffia, PAS, PZA, amikacin, streptomycin, ethionamide, viomycin, cycloserine, capreomycin, ciprofloxacin, imipenem, rifapentine, gentamicin, or penicillin. Group 1: AIDS patients with a first episode of Pneumocystis carinii pneumonia (PCP) within 2 to 4 months prior to study entry. Group 2: Patients with T4 counts < 100 cells/mm3, regardless of prior opportunistic infections or malignancies. Karnofsky = or > 70. All patients must sign informed consent.
Sites / Locations
- Keith Med Group
- San Francisco Gen Hosp